EYPT Nasdaq Laboratory Analytical Instruments Financials FY2015βFY2025
EyePoint, Inc. had $31.4M of revenue in fiscal 2025, down 27.5% on the year before. Over five years, revenue changed β1.8% a year on average.
Last close Β· Oct 23, 2026
$0.40
5.5%Hi! I read EyePoint, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β27.5%
No. Sales fell 27.5% last year.
Does it make a profit?
β739.4%
No. It lost money last year.
Does profit turn into cash?
β775.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days EyePoint, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Oct 17, 2026 | Period ended Sep 30, 2026 | Time not announced | 8-K β |
| Aug 5, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 6, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 7, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Oct 14, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 7, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· EyePoint, Inc. had $31.4M of revenue in fiscal 2025, down 27.5% on the year before. Over five years, revenue changed β1.8% a year on average. Its operating margin was β776.0%, down 438.9Β pts: of every 100 in sales, about β776 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· EyePoint, Inc. lost $232M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$243M in fiscal 2025, β775.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably EyePoint, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $212M | $145M | $331M | $371M | $306M |
| Debt incl. finance leases | $36.7M | $40.5M | $0.0M | β | β |
| Debt / equity | 0.2x | 0.4x | 0.0x | β | β |
| Interest coverage | β10.1x | β31.2x | β60.2x | β10,418.1x | β7,376.8x |
| Current ratio | 10.0x | 5.0x | 5.5x | 7.8x | 8.9x |
| Quick ratio | 9.9x | 4.9x | 5.4x | 7.8x | 8.8x |
| Total assets | $263M | $180M | $355M | $418M | $364M |
| Total liabilities | $79.0M | $84.0M | $88.9M | $82.0M | $57.9M |
| Shareholders' equity | $184M | $96.4M | $266M | $337M | $306M |
| Net debt (β = net cash) | β$175M | β$104M | β$331M | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· EyePoint, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY15 | FY16 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 1 / 7 | β / 3 | 4 / 8 | 5 / 8 | 4 / 8 | 2 / 8 | 6 / 8 | 2 / 7 | 1 / 7 |
| Accruals ratio | β16.5% | 8.0% | β40.0% | β0.1% | β37.6% | β4.7% | β16.8% | β27.1% | β1.2% | 2.1% |
| Altman Z'' | β27.55 | β53.94 | β16.13 | β22.34 | β17.17 | β0.67 | β9.61 | 0.11 | 0.41 | β3.58 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY15 | FY16 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.6M | $7.5M | $3.0M | $20.4M | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Research and development | $14.4M | $14.9M | $16.2M | $15.4M | $17.4M | $28.5M | $49.6M | $64.7M | $133M | $221M |
| Operating income | β$21.8M | β$18.6M | β$26.3M | β$47.9M | β$37.3M | β$55.3M | β$99.6M | β$75.1M | β$146M | β$243M |
| Interest expense | $0.0M | $0.0M | $0.7M | $6.2M | $7.3M | $5.5M | $3.2M | $1.2M | $0.0M | $0.0M |
| Pretax income | β$21.7M | β$18.5M | β$53.2M | β$56.8M | β$45.4M | β$58.4M | β$102M | β$70.7M | β$131M | β$232M |
| Income tax | β$0.2M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.3M |
| Net income | β$21.5M | β$18.5M | β$53.2M | β$56.8M | β$45.4M | β$58.4M | β$102M | β$70.8M | β$131M | β$232M |
| Diluted EPS | β$0.68 | β$0.52 | β$1.15 | β$5.44 | β$3.54 | β$2.03 | β$2.74 | β$1.82 | β$2.32 | β$3.17 |
| Diluted shares | 0.03B | 0.04B | 0.05B | 0.01B | 0.01B | 0.03B | 0.04B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$16.3M | β$20.5M | β$21.9M | β$56.7M | β$14.4M | β$50.1M | β$65.0M | $1.9M | β$126M | β$240M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.2M | $0.4M | $0.2M | $2.2M | $3.5M | $4.1M | $3.3M |
| Free cash flow | β$16.4M | β$20.6M | β$22.0M | β$56.9M | β$14.8M | β$50.3M | β$67.2M | β$1.6M | β$130M | β$243M |
| Depreciation and amortization | $0.2M | $0.1M | $0.2M | $0.1M | $0.2M | $0.3M | $0.4M | $0.5M | $1.5M | $2.3M |
| Stock-based compensation | $2.2M | $2.5M | $2.7M | $4.6M | $5.5M | $7.4M | $14.2M | $12.1M | $36.7M | $27.9M |
| Acquisitions | $0.0M | $0.0M | $16.8M | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $29.0M | $16.9M | $45.3M | $22.2M | $44.9M | $212M | $145M | $331M | $371M | $306M |
| Total debt | β | $0.0M | $17.6M | $47.2M | $38.0M | $36.6M | $40.5M | $0.0M | β | β |
| Finance lease liabilities | β | β | β | $0.0M | $0.2M | $0.2M | $0.0M | β | β | β |
| Current assets | $30.0M | $17.7M | $47.6M | $41.7M | $63.1M | $238M | $173M | $345M | $383M | $329M |
| Current liabilities | $5.1M | $5.3M | $21.5M | $11.5M | $14.9M | $23.7M | $34.5M | $63.3M | $49.0M | $37.0M |
| Inventory | β | $0.0M | $0.3M | $2.1M | $5.3M | $3.6M | $2.9M | $3.9M | $2.3M | $1.8M |
| Property and equipment, net | $0.3M | $0.3M | $0.3M | $0.4M | $0.6M | $0.5M | $1.4M | $5.3M | $8.2M | $9.0M |
| Intangible assets | $1.1M | $0.4M | $30.1M | $27.7M | $25.2M | $22.7M | $0.0M | β | β | β |
| Total assets | $31.6M | $18.7M | $78.2M | $73.0M | $91.7M | $263M | $180M | $355M | $418M | $364M |
| Total liabilities | $10.7M | $5.3M | $40.5M | $64.6M | $73.2M | $79.0M | $84.0M | $88.9M | $82.0M | $57.9M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $20.9M | $13.3M | $37.6M | $8.3M | $18.5M | $184M | $96.4M | $266M | $337M | $306M |
| Margins | ||||||||||
| Operating margin | β1,344.1% | β246.4% | β887.3% | β235.0% | β108.3% | β149.6% | β240.6% | β163.1% | β337.1% | β776.0% |
| EBITDA margin | β1,334.7% | β245.2% | β881.7% | β234.3% | β107.7% | β148.8% | β239.7% | β162.1% | β333.5% | β768.6% |
| Net margin | β1,330.1% | β245.2% | β1,795.7% | β278.9% | β131.8% | β158.1% | β247.0% | β153.8% | β302.4% | β739.4% |
| FCF margin | β1,014.1% | β273.7% | β743.5% | β279.5% | β43.0% | β136.0% | β162.2% | β3.5% | β301.1% | β775.8% |
| Returns | ||||||||||
| Return on capital | β | β | β207.7% | β113.4% | β253.8% | β465.3% | β | β | β | β |
| Return on capital employed | β82.1% | β138.8% | β46.3% | β77.9% | β48.5% | β23.1% | β68.3% | β25.7% | β39.5% | β74.5% |
| Return on equity | β103.2% | β108.0% | β141.3% | β247.1% | β337.9% | β57.6% | β72.8% | β39.0% | β43.4% | β72.2% |
| Return on assets | β68.1% | β73.5% | β68.0% | β75.2% | β55.1% | β32.9% | β46.1% | β26.4% | β33.8% | β59.3% |
| Return on tangible equity | β108.9% | β142.5% | β708.6% | β | β | β36.1% | β106.1% | β26.6% | β38.9% | β75.8% |
| Growth | ||||||||||
| Revenue growth | β | 365.4% | β | 587.8% | 69.1% | 7.3% | 12.1% | 11.1% | β6.0% | β27.5% |
| Share count change | β | 11.8% | β | β77.4% | 23.1% | 124.0% | 29.8% | β99.9% | 44.7% | 30.2% |
| Financial health | ||||||||||
| Debt / equity | β | 0.0x | 0.5x | 5.7x | 2.0x | 0.2x | 0.4x | 0.0x | β | β |
| Interest coverage | β | β | β36.5x | β7.7x | β5.1x | β10.1x | β31.2x | β60.2x | β10,418.1x | β7,376.8x |
| Current ratio | 5.9x | 3.4x | 2.2x | 3.6x | 4.2x | 10.0x | 5.0x | 5.5x | 7.8x | 8.9x |
| Quick ratio | 5.9x | 3.4x | 2.2x | 3.4x | 3.9x | 9.9x | 4.9x | 5.4x | 7.8x | 8.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 7.0% | 1.9% | 3.6% | 1.0% | 1.1% | 0.4% | 5.2% | 7.6% | 9.4% | 10.5% |
| Stock comp / revenue | 133.5% | 32.6% | 91.3% | 22.4% | 16.1% | 20.2% | 34.2% | 26.2% | 84.9% | 88.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 1.0 | β | 4.0 | 5.0 | 4.0 | 2.0 | 6.0 | 2.0 | 1.0 |
| Altman Z'' | β27.6 | β53.9 | β16.1 | β22.3 | β17.2 | β0.7 | β9.6 | 0.1 | 0.4 | β3.6 |
| Accruals ratio | β16.5% | 8.0% | β40.0% | β0.1% | β37.6% | β4.7% | β16.8% | β27.1% | β1.2% | 2.1% |
Source: SEC EDGAR XBRL filings (CIK 0001314102). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
